Ponatinib (Iclusig) is a potent tyrosine kinase inhibitor that plays a crucial role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML).

Dosage and Administration of Ponatinib (Iclusig)

1. Newly Diagnosed Ph+ ALL

Initial dose: 30 mg once daily in combination with chemotherapy.

After the induction phase, if a minimal residual disease (MRD)-negative complete remission (CR) is achieved, reduce the dose to 15 mg once daily.

Continue treatment for up to 20 cycles, or until disease progression or intolerable toxicity occurs.

2. Single-Agent Treatment for Ph+ ALL

Initial dose: 45 mg once daily.

If no response is observed within 3 months, consider discontinuing the medication.

3. Chronic Phase (CP) CML

Initial dose: 45 mg once daily.

After achieving a BCR::ABL1 IS (international scale) ≤ 1%, reduce the dose to 15 mg once daily.

If loss of response occurs, the dose may be re-escalated to 30 mg or 45 mg once daily.

4. Accelerated Phase (AP) / Blastic Phase (BP) CML

Initial dose: 45 mg once daily.

For patients with accelerated phase CML who achieve a major cytogenetic response, consider dose reduction.

Administration Guidelines

1. Route of Administration

Oral administration. The medication can be taken with or without food.

2. Dosage Form Handling

Swallow the tablet whole. Chewing, crushing, or splitting the tablet is prohibited.

3. Management of Missed Doses

Do not make up for the missed dose. Take the next scheduled dose at the original planned time.

Dose Adjustments of Ponatinib (Iclusig)

1. Arterial Occlusive Events (AOEs)

For grade ≥ 3 AOEs: Permanent discontinuation of the medication is required.

For grade 1-2 cardiovascular/cerebrovascular AOEs: Interrupt treatment until recovery.

2. Venous Thromboembolic Events

For grade 1 events: Suspend treatment until recovery.

For grade ≥ 2 events: Permanent discontinuation of the medication is required.

3. Heart Failure

For newly onset or worsening heart failure: Interrupt treatment. After recovery, resume treatment at a reduced dose.

4. Pancreatitis

For asymptomatic lipase elevation (1.5-2 times the upper limit of normal): Continue treatment at the original dose.

For symptomatic pancreatitis or lipase elevation > 5 times the upper limit of normal: Permanent discontinuation of the medication is required.

Use in Special Populations

1. Patients with Hepatic or Renal Impairment

For single-agent treatment of CP/AP/BP-CML and Ph+ ALL: Reduce the initial dose from 45 mg to 30 mg once daily.

For newly diagnosed Ph+ ALL patients with mild hepatic impairment: No dose adjustment is needed. For those with moderate to severe hepatic impairment, close monitoring is required.

2. Geriatric Patients

Clinical data show that the incidence of serious adverse events is higher in patients aged 65 years and older (34% vs. 24%). Special attention should be paid to cardiovascular events.

3. Pregnancy and Lactation

(1) Pregnancy

Ponatinib has embryo-fetal toxicity. Patients should be informed of the risks and advised to use effective contraceptive measures.

(2) Lactation

Breastfeeding is prohibited during treatment and for 1 week after the last dose.